Protective effect of forphenicinol, a low molecular weight immunomodifier, against infection with Pseudomonas aeruginosa in mice and its mechanisms.
The oral administration of forphenicinol increased the survival rate of both normal and immunodepressed mice intraperitoneally or intratracheally infected with clinically isolated strains of Pseudomonas aeruginosa. The therapeutic effect of amikacin on intraperitoneal infection with P. aeruginosa was enhanced by combined use with forphenicinol. Forphenicinol did not enhance the bactericidal activity of polymorphonuclear cells (PMN) towards P. aeruginosa in vitro, but enhanced it in vivo. In vitro study indicated that the macrophages taken from mice treated with forphenicinol or the cultured supernatant of these macrophages enhanced the bactericidal activity of PMN. The protective effect of forphenicinol against P. aeruginosa infection was thus suggested to be due to macrophage activation followed by the enhancement of the bactericidal activity of PMN.
D000276:Adjuvants, Immunologic; D000583:Amikacin / Q000627:therapeutic use; D000818:Animals; D005260:Female; D005998:Glycine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051379:Mice; D008813:Mice, Inbred ICR; D009113:Muramidase / Q000097:blood; D009504:Neutrophils / Q000378:metabolism; D011552:Pseudomonas Infections / Q000276:immunology* / Q000517:prevention & control; D011550:Pseudomonas aeruginosa / Q000276:immunology; D013481:Superoxides / Q000097:blood
D000276:Adjuvants, Immunologic; D013481:Superoxides; C035946:forphenicinol; D000583:Amikacin; D009113:Muramidase; D005998:Glycine